|
Market Closed -
Nasdaq
21:00:00 02/10/2026 BST
|
5-day change | 1st Jan Change | ||
| 0.8022 USD | -7.45% |
|
-50.48% | -89.10% |
| 08-31 | Karyopharm Therapeutics Submits Supplemental New Drug Application to the Fda for Xpovio Plus Ruxolitinib for Patients with Myelofibrosis | CI |
| 08-29 | Karyopharm Therapeutics Inc. - Special Call |
| Market Cap | 18.2M 16.17M 15.09M 13.75M 25.94M 1.75B 26.18M 183M 70.76M 894M 68.31M 66.83M 2.87B | P/E 2026 * |
-0.17x | P/E 2027 * | -0.34x |
|---|---|---|---|---|---|
| Enterprise Value | 18.2M 16.17M 15.09M 13.75M 25.94M 1.75B 26.18M 183M 70.76M 894M 68.31M 66.83M 2.87B | EV / Sales 2026 * |
0.13x | EV / Sales 2027 * | 0.1x |
| Free-Float |
95.33% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| KPTI | Delayed | |
CBOE
| KPTI | Real-time | |
|
Tradegate
| 25K0 | Real-time | |
|
Boerse Muenchen
| 25K0 | Real-time | |
|
Deutsche Boerse AG
| 25K0 | Delayed | |
|
Börse Stuttgart
| 25K0 | Delayed |
Last Transcript: Karyopharm Therapeutics Inc.
| 1 day | -7.45% | ||
| 1 week | -50.48% | ||
| Current month | -34.25% | ||
| 1 month | -54.68% | ||
| 3 months | -91.64% | ||
| 6 months | -86.38% | ||
| Current year | -89.10% |
| 1 week | 0.75 |  | 1.66 |
| 1 month | 0.75 | | 1.93 |
| Current year | 0.75 | | 10.99 |
| 1 year | 0.75 | | 10.99 |
| 3 years | 0.75 | | 29.25 |
| 5 years | 0.75 | | 220.95 |
| 10 years | 0.75 | | 444.15 |
| Manager | Title | Age | Since |
|---|---|---|---|
Richard Paulson
CEO | Chief Executive Officer | 58 | 02/05/2021 |
Lori Macomber
DFI | Director of Finance/CFO | 55 | 02/01/2025 |
Amama Sadiq
CTO | Chief Tech/Sci/R&D Officer | - | 31/03/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
Barry Greene
BRD | Director/Board Member | 63 | 31/12/2012 |
| Director/Board Member | 61 | 31/03/2013 | |
Garen Bohlin
BRD | Director/Board Member | 78 | 02/10/2013 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 01/09/26 | Sell | Controller/Auditor | -19 | 0.0001% | ||
| 28/07/26 | Sell | Executive/Senior Manager | -189 | 0.0008% | ||
| 21/05/26 | Free | Director | 15,508 | 0.0688% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -7.45% | -50.48% | -87.43% | -95.84% | 18.2M | |
| -0.61% | -3.43% | +36.07% | +117.61% | 1,019B | |
| -1.02% | -5.60% | +35.72% | +64.82% | 617B | |
| +1.11% | -0.58% | +12.36% | +78.27% | 464B | |
| +0.34% | -3.01% | +61.79% | +41.79% | 356B | |
| -0.95% | -4.05% | +20.54% | +40.33% | 333B | |
| -1.46% | -2.89% | +10.57% | +26.54% | 267B | |
| -1.35% | -5.43% | -6.17% | +8.82% | 244B | |
| -1.04% | -2.79% | +35.30% | +54.42% | 218B | |
| -1.87% | -4.10% | +28.44% | +97.54% | 179B | |
| Average | -1.43% | -8.10% | +14.72% | +43.43% | 369.72B | |
| Weighted average by Cap. | -0.60% | -3.33% | +29.07% | +71.15% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 136M 121M 112M 103M 193M 13.04B 195M 1.36B 527M 6.67B 509M 498M 21.39B | 174M 154M 144M 131M 247M 16.69B 250M 1.74B 675M 8.53B 652M 638M 27.38B |
| Net income | -160M -142M -133M -121M -228M -15.4B -230M -1.61B -623M -7.87B -601M -588M -25.26B | -115M -102M -95.28M -86.84M -164M -11.05B -165M -1.15B -447M -5.65B -431M -422M -18.12B |
| Net Debt | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 02/10/26 | US$0.8022 | -7.45% | 2,341,758 |
| 01/10/26 | US$0.8668 | -28.95% | 2,659,950 |
| 30/09/26 | US$1.220 | +1.24% | 1,754,326 |
| 29/09/26 | US$1.205 | -25.62% | 1,870,182 |
| 28/09/26 | US$1.620 | 0.00% | 331,072 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- KPTI Stock
Select your edition
All financial news and data tailored to specific country editions
